Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 20 versus ADHANSIA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 20 versus ADHANSIA XR.
ADDERALL XR 20 vs ADHANSIA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 20 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine). It increases synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
20 mg orally once daily in the morning.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
None Documented
None Documented
Approximately 10-13 hours for d-amphetamine and 13-15 hours for l-amphetamine in adults; in children, 9-11 hours. The extended-release formulation provides a prolonged therapeutic effect masking shorter elimination.
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Approximately 90% of an oral dose is excreted renally, with 30% as unchanged amphetamine and the remainder as metabolites (including hippuric acid, benzoic acid, and hydroxylated derivatives). Fecal/biliary excretion accounts for <10%.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant